Shots:

• The company has signed a supply agreement for 2 anticancer biosimilars- Herzuma (trastuzumab) and Truxima (rituximab) in Brazil. The supply of Herzuma accounts for ~80% of Brazil's trastuzumab market
• Additionally- the company also won orders from eight state governments in Brazil for Truxima- including a bid in Sao Paulo. Following this- the company plans to expand its presence in Latin America
• In March 2021- the company has initiated direct sales of infliximab biosimilar in Colombia and plans for rituximab and trastuzumab biosimilars in June & July respectively. The company also plans to expand its sales in Peru and Chile in Q3’21

 to   | Ref: Celltrion | Image: Celltrion